Full Title
An Open-Label, Phase I/II Study to Evaluate The Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (Ro7227166, A Cd19 Targeted 4-1bb Ligand) In Combination with Obinutuzumab and in Combination with Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s LymphomaPurpose
Researchers want to find the best dose of englumafusp alfa, given in combination with glofitamab, to treat lymphoma. The people in this study have large B-cell lymphoma that came back or keeps growing after treatment.
Englumafusp alfa is a bispecific antibody. It binds to two different proteins: one on cancer cells and another on immune cells. Englumafusp alfa may strengthen your immune system’s ability to fight cancer by activating your own cells to destroy your tumor. It is given intravenously (by vein).
Glofitamab is also a bispecific antibody and works in a similar way to help the immune system fight cancer cells. It, too, is given intravenously.
Who Can Join
To join this study, there are a few conditions. You must:
- Have large B-cell lymphoma that came back or keeps growing after treatment.
- Have recovered from the serious side effects of prior therapies before receiving the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Lorenzo Falchi’s office at 646-608-3705.